These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 14761803

  • 21. Considerations in compound database preparation--"hidden" impact on virtual screening results.
    Knox AJ, Meegan MJ, Carta G, Lloyd DG.
    J Chem Inf Model; 2005; 45(6):1908-19. PubMed ID: 16309298
    [Abstract] [Full Text] [Related]

  • 22. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H, Kim YJ, Hahn JS.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6345-9. PubMed ID: 17869098
    [Abstract] [Full Text] [Related]

  • 23. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC.
    Curr Opin Drug Discov Devel; 2008 May 15; 11(3):356-64. PubMed ID: 18428089
    [Abstract] [Full Text] [Related]

  • 24. Analysis and optimization of structure-based virtual screening protocols (1): exploration of ligand conformational sampling techniques.
    Good AC, Cheney DL.
    J Mol Graph Model; 2003 Sep 15; 22(1):23-30. PubMed ID: 12798388
    [Abstract] [Full Text] [Related]

  • 25. Exploring the chemogenomic knowledge space with annotated chemical libraries.
    Savchuk NP, Balakin KV, Tkachenko SE.
    Curr Opin Chem Biol; 2004 Aug 15; 8(4):412-7. PubMed ID: 15288252
    [Abstract] [Full Text] [Related]

  • 26. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
    Langer T, Krovat EM.
    Curr Opin Drug Discov Devel; 2003 May 15; 6(3):370-6. PubMed ID: 12833670
    [Abstract] [Full Text] [Related]

  • 27. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example.
    Rollinger JM, Haupt S, Stuppner H, Langer T.
    J Chem Inf Comput Sci; 2004 May 15; 44(2):480-8. PubMed ID: 15032527
    [Abstract] [Full Text] [Related]

  • 28. High-throughput virtual screening for drug discovery in parallel.
    Toledo-Sherman LM, Chen D.
    Curr Opin Drug Discov Devel; 2002 May 15; 5(3):414-21. PubMed ID: 12058617
    [Abstract] [Full Text] [Related]

  • 29. A similarity-based data-fusion approach to the visual characterization and comparison of compound databases.
    Medina-Franco JL, Maggiora GM, Giulianotti MA, Pinilla C, Houghten RA.
    Chem Biol Drug Des; 2007 Nov 15; 70(5):393-412. PubMed ID: 17927720
    [Abstract] [Full Text] [Related]

  • 30. Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors.
    Krüger DM, Evers A.
    ChemMedChem; 2010 Jan 15; 5(1):148-58. PubMed ID: 19908272
    [Abstract] [Full Text] [Related]

  • 31. In silico fragment-based discovery of DPP-IV S1 pocket binders.
    Rummey C, Nordhoff S, Thiemann M, Metz G.
    Bioorg Med Chem Lett; 2006 Mar 01; 16(5):1405-9. PubMed ID: 16321524
    [Abstract] [Full Text] [Related]

  • 32. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.
    Park H, Li M, Choi J, Cho H, Ham SW.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4372-5. PubMed ID: 19500977
    [Abstract] [Full Text] [Related]

  • 33. Unconventional 2D shape similarity method affords comparable enrichment as a 3D shape method in virtual screening experiments.
    Ebalunode JO, Zheng W.
    J Chem Inf Model; 2009 Jun 01; 49(6):1313-20. PubMed ID: 19480404
    [Abstract] [Full Text] [Related]

  • 34. Discovery of novel cathepsin S inhibitors by pharmacophore-based virtual high-throughput screening.
    Markt P, McGoohan C, Walker B, Kirchmair J, Feldmann C, De Martino G, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T.
    J Chem Inf Model; 2008 Aug 01; 48(8):1693-705. PubMed ID: 18637674
    [Abstract] [Full Text] [Related]

  • 35. Flexible 3D pharmacophores as descriptors of dynamic biological space.
    Nettles JH, Jenkins JL, Williams C, Clark AM, Bender A, Deng Z, Davies JW, Glick M.
    J Mol Graph Model; 2007 Oct 01; 26(3):622-33. PubMed ID: 17395510
    [Abstract] [Full Text] [Related]

  • 36. Virtual screening - what does it give us?
    Köppen H.
    Curr Opin Drug Discov Devel; 2009 May 01; 12(3):397-407. PubMed ID: 19396741
    [Abstract] [Full Text] [Related]

  • 37. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep 01; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 38. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches.
    Pirard B, Brendel J, Peukert S.
    J Chem Inf Model; 2005 Sep 01; 45(2):477-85. PubMed ID: 15807513
    [Abstract] [Full Text] [Related]

  • 39. Comparative evaluation of 3D virtual ligand screening methods: impact of the molecular alignment on enrichment.
    Giganti D, Guillemain H, Spadoni JL, Nilges M, Zagury JF, Montes M.
    J Chem Inf Model; 2010 Jun 28; 50(6):992-1004. PubMed ID: 20527883
    [Abstract] [Full Text] [Related]

  • 40. Towards improving compound selection in structure-based virtual screening.
    Waszkowycz B.
    Drug Discov Today; 2008 Mar 28; 13(5-6):219-26. PubMed ID: 18342797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.